Daewoong Pet announced on the 15th that it will host an in-person symposium titled “Latest Research and Treatment Strategies for Gastrointestinal Disorders and Diabetes” on August 28 at Daewoong Pharmaceutical’s Bear Hall in Samseong-dong, Gangnam, Seoul. The event is targeted at veterinarians and professionals in the companion animal healthcare industry.

The symposium aims to provide in-depth discussion on the latest advancements in the treatment of pancreatic disease, microbiome-related conditions, hepatobiliary disorders, and diabetes in pets. CEO Hyojoon Lee of Daewoong Pet will open the event, followed by expert-led sessions:

“Diabetes Management in Dogs: A Literature Review of Recent Studies”
by Professor Juhyun Ahn, Kangwon National University

“Trends in Microbiome Research and the Canine Microbiome”
by Ilhwan Kim, CEO of V1 Bio

“When the Liver and Gallbladder Are in Trouble: Insights into Hepatobiliary Disease”
by Dr. Seolgi Park, Incheon SKY Animal Medical Center

“Pancreatitis Management in Geriatric Chronic Disease Patients”
by Dr. Yoonji Lim, Director of VIP Companion Animal Cancer Center

With evolving pet lifestyles, diets, and increasing life expectancy, the incidence of gastrointestinal disorders and diabetes in companion animals is on the rise. This symposium provides a platform for exchanging clinical experiences, exploring innovative therapeutic techniques, and sharing the latest scientific insights to improve treatment outcomes.

As part of its continuing innovation, Daewoong Pet recently launched Korea’s first veterinary UDCA tablet, UDCA Chewable (Ursodeoxycholic Acid). The product enhances palatability with pet-friendly ingredients and comes in a chewable form for easier administration. It uses high-purity UDCA sourced from Daewoong Bio, which supplies over 25% of the global UDCA market, ensuring exceptional ingredient quality.

Daewoong Pet has been actively expanding its product line in digestive and liver health. In July 2023, the company released Epicl, a pancreatic enzyme supplement containing pancreatin and lipase—essential digestive enzymes that support the breakdown of carbohydrates, proteins, and fats. Within just 11 months, Epicl surpassed 20,000 cumulative units sold, securing a strong position in the pancreatitis adjunct therapy market.

In March 2024, Daewoong Pet launched AlphaNex, a probiotic-enzyme complex available exclusively through veterinary clinics. The product features Limosilactobacillus reuteri VA102, a patented strain derived from healthy beagle microbiota, supporting gut health and nutrient absorption in dogs.

CEO Hyojoon Lee emphasized:

“This symposium serves as a critical platform to share the latest research and therapeutic strategies for a wide range of diseases affecting companion animals.
At Daewoong Pet, we remain committed to developing prescription veterinary products and animal pharmaceuticals that meaningfully enhance pet health and quality of life.”